UroAlert - GU Oncology Daily

July 24, 2026

Videos

Peer-to-Peer Clinical Conversations

Impact of Dose Holds and Reductions on Survival in the UNITE EV Cohort - Jeffrey Zhong

Jeffrey Zhong

Jeffrey Zhong discusses a retrospective UNITE consortium analysis of dose modifications of enfortumab vedotin plus pembrolizumab in 360 patients with advanced urothelial carcinoma.

View

MEVPRO-3 Trial: Enzalutamide with or Without Mevrometostat in Metastatic Hormone-Sensitive Prostate Cancer - Neeraj Agarwal

Neeraj Agarwal

Neeraj Agarwal describes the MEVPRO-3 trial design.

View

Beyond the Abstracts

Outcomes of Immune-Checkpoint Inhibitor Rechallenge in Metastatic Clear-Cell Renal Cell Carcinoma: Results from a Global Real-World Evidence Study - Beyond the Abstract

Neoadjuvant Sacituzumab Govitecan plus Pembrolizumab, Followed by Adjuvant Pembrolizumab, in Patients with Muscle-Invasive Bladder Cancer (SURE-02): A Single-Arm, Phase 2 Study - Beyond the Abstract

Conference Coverage

ASCO 2026: Ultrasensitive ctDNA Detection and Molecular Clearance as a Prognostic and Predictive Marker in Advanced RCC

ASCO 2026: Initial Results from EXCEED, a Phase 1 Study of LY4101174, an Antibody-Drug Conjugate Targeting Nectin-4, in Participants with Advanced or Metastatic Urothelial Carcinoma

ASCO 2026: Patient Experiences with UGN-102 for Recurrent Low Grade Intermediate Risk NMIBC: Insights for Shared Decision Making

AUA 2026: First Results from CORE-008 Cohort CX- Phase 2 Study of Intravesical Cretostimogene Grenadenorepvec with Gemcitabine in Patients with High-Risk BCG-Exposed or BCG-Unresponsive Non-Muscle Invasive Bladder Cancer

EAU 2026: Adjuvant Pembrolizumab + Belzutifan for Clear Cell RCC: Primary and Exploratory Efficacy Outcomes from the Phase 3 LITESPARK-022 Study

Articles

Editor Selected Abstracts and Commentaries

CONNECT WITH US

Questions or Comments? Email us at editors@urotoday.com

Digital Science Press, LLC
2011 Phaethon Lane,
Reno, NV 89523

You are receiving this email because you have chosen to receive emails from UroToday.

UroAlert - GU Oncology Daily

Bladder Cancer

Renal Cancer

Prostate Cancer

Upper Tract Tumors

Login